Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Summary

The purpose of this study in patients with schizophrenia is to evaluate the safety, tolerability, and pharmacokinetics of 3 doses (low, mid, high) of APN1125 compared with placebo when administered as repeated daily oral doses.

Timeline

Start

2016-04

Primary completion

2016-09

Completion

2016-12

Outcome

Outcome not reported

Stopped (Business): “Study halted by sponsor for business reasons”

Drugs

Indications